Discover how personalized ctDNA testing is transforming care for patients with muscle-invasive bladder cancer (MIBC). This 30-minute webinar includes results from two landmark Phase 3 studies—IMvigor011 and CheckMate 274—that demonstrate the clinical utility of personalized Signatera™ MRD testing in the adjuvant management of MIBC.